Specific PROTACs targeting GR or FKBP5 may cause systemic side effects such as immune dysfunction or disrupted stress hormone regulation, highlighting the need for improved specificity and reduced toxicity in PROTAC design for stress-related disorders. This evidence concerns the gene FKBP5 and immune system disorder.